New York, NY (PRWEB) May 17, 2016
Dr. Joan Fallon, founder and CEO of Curemark, was recognized last night at the Fred and Adele Astaire Awards Gala at the Skirball Center for the Performing Arts. Dr. Fallon was bestowed with the Special Achievement Award for Work in the Field of Autism and Related Disorders. The event celebrated the 2016 season’s outstanding dance & choreography on Broadway and film, and proceeds benefited The Douglas Watt Family Fund for the Performing Arts (DWFFPA). The DWFFPA provides a public school-based program of dance and movement therapy aimed at addressing the unique needs of children with autism and other developmental disabilities.
“It is an incredible honor to be recognized by an organization that supports therapies for children with autism and other disabilities,” says Dr. Fallon. “Children with autism have difficulty with sensory integration and dance is a fabulous way to address that problem.”
Dance therapy is the use of movement for emotional, cognitive, social, behavioral and physical growth. Dance is designed to foster an atmosphere of creative freedom and socialization where children will be empowered to express themselves.
“There is a need for more in-school programs for children on the spectrum,” says Dr. Fallon. “The support by The Fred and Adele Astaire Awards and The Douglas Watt Family Fund for the Performing Arts in implementing dance and movement classes in public schools gives the children tremendous benefits that they might not receive elsewhere.”
Also awarded at The Fred and Adele Astaire Awards included dancer and choreographer Judith Jamison, dancer and “So You Think You Can Dance Host” Nigel Lythgoe, and actor and choreographer Maurice Hines. Additional winners included Savion Glover and Jane Krakowski.
Curemark, LLC is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological disorders. Curemark’s pipeline includes preclinical and clinical-stage programs for the treatment of Autism, ADHD, addiction, Schizophrenia and Parkinson’s disease. For additional information, please visit http://www.curemark.com or follow @curemark on Twitter.
CM-AT, Curemark’s lead drug candidate, has been granted “Fast Track” designation by the U.S. Food and Drug Administration for the investigation of Autism. The company is currently enrolling a Phase III double blind, randomized, placebo-controlled clinical trial (known as the Blüm Study) to examine the effect of CM-AT in children ages 3-8 with Autism. The trial is enrolling in over 20 sites across the United States. For additional information, please see: http://www.blumstudy.com.